Arvest Investments Inc. Decreases Stake in IQVIA Holdings Inc. (NYSE:IQV)

Arvest Investments Inc. lowered its position in IQVIA Holdings Inc. (NYSE:IQV) by 7.1% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 9,350 shares of the medical research company’s stock after selling 715 shares during the period. Arvest Investments Inc.’s holdings in IQVIA were worth $1,837,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Smith Group Asset Management LLC purchased a new position in IQVIA in the 4th quarter valued at $1,616,000. Nordea Investment Management AB raised its holdings in shares of IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after acquiring an additional 452,029 shares during the period. Hickory Asset Management Inc. purchased a new position in shares of IQVIA during the 4th quarter worth $941,000. Fifth Third Bancorp raised its holdings in shares of IQVIA by 13.0% during the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock worth $2,590,000 after acquiring an additional 1,521 shares during the period. Finally, Graphene Investments SAS raised its holdings in shares of IQVIA by 22.0% during the 4th quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company’s stock worth $2,948,000 after acquiring an additional 2,700 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Down 0.9 %

IQV stock opened at $186.80 on Thursday. The company’s 50 day moving average price is $195.71 and its 200 day moving average price is $209.36. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a fifty-two week low of $179.28 and a fifty-two week high of $256.29. The firm has a market capitalization of $32.93 billion, a price-to-earnings ratio of 24.91, a PEG ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently commented on IQV. Royal Bank of Canada reiterated an “outperform” rating and set a $270.00 price target on shares of IQVIA in a report on Monday, February 10th. Robert W. Baird reduced their price target on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, January 21st. Bank of America cut their price objective on IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, December 13th. UBS Group cut their price objective on IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Finally, BTIG Research downgraded IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Five analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $249.05.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.